Who’s Hired? Alvotech Names New COO After Refiling Adalimumab
As Strides’ Strategy Head Departs And Haggar Becomes Biocon Director
Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.
